Burney Co/ 13F: New $8.9M Stake in CareDx (CDNA)

Burney Co. has initiated a new position in CareDx, Inc. (CDNA) as disclosed in a filing on October 15, 2026. The firm acquired 136,338 shares valued at approximately $8.86 million. This marks Burney Co.'s first involvement with CareDx, reflecting a strategic entry into the healthcare diagnostics sector.

Other Institutional Activity in CareDx, Inc.

BlackRock Inc. increased its holdings by 292,582 shares, bringing its total to 4,814,709 shares worth about $308.1 million. Meanwhile, State Street Corporation reduced its stake by 291,493 shares, ending with 2,468,858 shares valued at approximately $158.0 million. Vanguard Capital Management LLC added 36,945 shares to its position, now holding 2,197,475 shares valued at around $140.6 million. In contrast, Deerfield Management Company, L.P, trimmed its investments, selling 193,473 shares to hold 1,997,618 shares worth about $127.8 million. ARK Investment Management, LLC also cut its position, decreasing its shares by 273,984, resulting in 1,953,531 shares valued at approximately $125.0 million.

CareDx, Inc. Stock Down 4.8%

As of October 16, 2026, CareDx's stock trades recently around $63.50. This price is above its 50-day moving average by 16.4% and significantly above its 200-day moving average by 106.2%. However, it is 12.4% below its 52-week high of $72.51. The stock has shown strong growth, trading well above its 52-week low of $14.03.

Recent Earnings

CareDx reported trailing twelve-month (TTM) revenue of $458.1 million, reflecting a year-over-year growth of 52.2%. The company has achieved an impressive net margin of 24.2% and a return on equity (ROE) of 29.5%. Its next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at CareDx, Inc.

Recently, CareDx's President and CEO, John Walter Hanna Jr., made several transactions. On June 29, 2026, he bought 39,900 shares at an average price of $8.20, totaling approximately $327,180. Later on the same day, he also sold 39,900 shares at a price of $29.24, valued at over $1.16 million. Earlier, on June 15 and June 26, he sold 100 shares and 17,683 shares in planned transactions, worth $2,900 and $424,922.49, respectively.

Analysts Set New Price Targets

Analysts have been optimistic about CareDx's prospects. On July 16, 2026, BTIG maintained a "Buy" rating with a price target of $45.00, which was later raised to $74.00 on September 24, 2026. Canaccord Genuity initiated coverage on September 2, 2026, with a "Buy" rating and a target of $65.00. The consensus recommendation among analysts is a "Buy" with a mean price target of $61.67, indicating confidence in the company’s growth potential.

About CareDx, Inc.

CareDx, Inc. is a healthcare company that focuses on improving outcomes for transplant patients. It offers several diagnostic solutions, including AlloSure, a donor-derived cell-free DNA test for kidney and heart transplant patients, and AlloMap, a gene expression profiling solution. The firm operates in the U.S. and internationally, with a commitment to advancing organ health.

Bottom Line

Investors should note that the 13F filing reflects Burney Co.'s holdings as of the reporting period and may not represent its current position. With its next earnings report due on October 29, 2026, CareDx remains a company to watch in the diagnostics space.